Following the amendment to the Economic Competition Law, the Israeli Competition Authority, on February 3, 2019, published for a public hearing a draft guidance paper on how to determine the existence of significant market power.
On January 10, 2019, an amendment to the Economic Competition Law came into force dealing with the definition of a monopoly. According to the previous version of the Law, a corporation was considered a monopolist if it controlled more than half the supply or purchase of a product or service. According to the amendment, a monopolist will now also include anyone who has significant economic market power. In light of this amendment, the need arose to clarify how the Authority believes that the existence of significant market power should be determined.
As the guidance paper explains, significant market power is the power to charge a price that is significantly higher than the price that would be charged in a competitive market. When a company with market power considers whether to raise the prices that it charges the public, it does not have to worry about the expected reaction of customers nor the expected response of other suppliers.
The guidance paper gives a list of characteristics relevant to examining significant market power, including market share, the number and standing of competitors in the same sector, volatility of market share, the degree of differentiation between products in the sector, the importance of the product for retailers, and the existence of barriers to transfer for customers.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas